@article{10902/34534,
year = {2024},
url = {https://hdl.handle.net/10902/34534},
abstract = {Background: Aspirin and statins have been suggested to have potential chemopreventive effects against gastric cancer (GC), although the results of previous studies have been inconsistent. This study therefore aimed to investigate the association between the use of aspirin and statins and GC. Methods: A pooled analysis of seven case-control studies within the Stomach Cancer Pooling Project, including 3220 cases and 9752 controls, was conducted. Two-stage modeling analyses were used to estimate the association between aspirin and statin use and GC after adjusting for potential confounders. Results: The pooled odds ratio (OR) of GC for aspirin users versus nonusers was 0.72 (95% confidence interval [CI], 0.54-0.95). The protective effect of aspirin appeared stronger in individuals without a GC family history (OR, 0.60; 95% CI, 0.37-0.95), albeit with borderline heterogeneity between those with and without a family history (p = .064). The OR of GC decreased with increasing duration of aspirin use, with an OR of 0.41 (95% CI, 0.18-0.95) for durations of ≥15 years. An inverse, nonsignificant association with the risk of GC was observed for the use of statins alone (OR, 0.79; 95% CI, 0.52-1.18). Conclusions: These findings suggest that aspirin use, particularly long-term use, is associated with a reduced risk of GC, whereas a similar association was not observed with statins, possibly because of the low frequency of use.},
organization = {Funding information: Associazione Italiana per la Ricerca sul Cancro, Grant/Award Number: 21378; Ministero dell’Istruzione, dell’Università e della Ricerca, Grant/Award Number: 2022A4WZFC. Acknowledgments: this study was funded by the Associazione Italiana per la Ricerca sul Cancro (Project 21378 to Carlo La Vecchia) and by the Italian Ministry of Education, University and Research (PNRR per la Missione 4, Componente 2, Investimento1.1.Avviso 104/2022 Finanziato dall'Unione Europea–Next Generation EU Progetto MUR PRIN prot 2022A4WZFC to Stefania Boccia). Nuno Lunet and Samantha Morais are supported by national funds via the Foundation for Science and Technology (FCT) within the scope of Projects UIDB/04750/2020 and LA/P/0064/2020. Samantha Morais also received funding under the scope of Project “NEON‐PC—Neuro‐oncological complications of prostate cancer: Longitudinal study of cognitive decline” (POCI‐01‐ 0145‐FEDER‐032358; Reference PTDC/SAU‐EPI/32358/2017) funded by Fundo Europeu de Desenvolvimento Regional via the Operational Program “Competitiveness and Internationalisation,” national funding from the FCT, and EPIUnit–Junior Research–Prog financing (UIDP/04750/2020). This research was supported in part by the Intramural Research Program of the US National Cancer Institute. The authors thank the European Cancer Prevention Organization for providing support for project meetings. Open access publishing facilitated by Universita degli Studi di Bologna, as part of the Wiley ‐ CRUI‐CARE agreement.},
publisher = {Wiley},
publisher = {Cancer, 2024, 1-11},
title = {Aspirin but not statins is inversely related to gastric cancer with a duration-risk effect: results from the Stomach Cancer Pooling Project Consortium},
author = {Pastorino, Roberta and Pires Marafon, Denise and Sassano, Michele and Hoxhaj, Ilda and Pelucchi, Claudio and Liao, Linda M. and Rabkin, Charles S. and Sinha, Rashmi and Lunet, Nuno and Morais, Samantha and Zaridze, David and Maximovich, Dmitry and Aragonés, Nuria and Castaño-Vinyals, Gemma and Gómez Acebo, Inés and López-Carrillo, Lizbeth and López-Cervantes, Malaquías and Bonzi, Rossella and Turati, Federica and Boffetta, Paolo},
}